INVESTOR RELATIONS

Investor relations

PRESS RELEASES

Lipum AB (publ) ("Lipum" or the "Company") announces that the subscription period in the Company’s capital raising begins today...
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES, AUSTRALIA, HONG KONG, JAPAN, CANADA...
An Extraordinay General Meeting (the ”EGM”) in Lipum AB (publ), corporate identity number 556813-5999 (”Lipum” or the “Company”)...
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES, AUSTRALIA, HONG KONG, JAPAN, CANADA...
Do not miss Lipum's presentation at the BioStock Life Science Spring Summit, today May 31 at 10.40. The event starts at 10.00 - see the full programme...
Lipum AB (publ) has published the interim report for period January to March for 2023. Below is a summary, a complete report (only in Swedish) is available...
2023-03-24 08:00 Lipum AB – Year-end report 2022 Regulatory
Lipum AB (publ) has published the interim and the year-end report for 2022. Below is a summary, a complete report (only in Swedish) is available on the...
Lipum AB (publ) announces that the clinical phase 1 study with the drug candidate SOL-116 is proceeding as planned. After a fourth dose escalation, a safety...
Lipum (publ), a clinical stage biopharmaceutical company focused on chronic inflammatory diseases, today announced its participation in the following upcoming...
Lipum AB (publ) ("Lipum") announces its Nomination Committee for the Annual General Meeting 2023. In accordance with the decision at the Annual...

INVESTOR RELATIONS

Investor relations